section name header

Indications ⬇

High Alert


Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Drug-drug:

Drug-Natural Products:

Drug-Food:

Availability ⬆ ⬇

(Generic available)

Route/Dosage ⬆ ⬇

Acute Myeloid Leukemia

Aggressive Systemic Mastocytosis, Systemic Mastocytosis with Associated Hematological Neoplasm, or Mast Cell Leukemia

US Brand Names ⬆ ⬇

Rydapt

Action ⬆ ⬇

  • Inhibits FLT3 receptor signaling and cell proliferation, and induces apoptosis in ITD- and TKD-mutant expressing leukemic cells, as well as in cells overexpressing wild type FLT3 and PDGFR. It also may inhibit KIT signaling, cell proliferation, and histamine release (and induces apoptosis) in mast cells.
Therapeutic effects:
  • Improved survival in AML.
  • Improved complete or incomplete remission rates in systemic mastocytosis.

Classifications ⬆ ⬇

Therapeutic Classification: antineoplastics

Pharmacologic Classification: kinase inhibitors

Pharmacokinetics ⬆ ⬇

Absorption: Absorption increased with food (especially a high-fat meal).

Distribution: Extensively distributed to tissues.

Protein Binding: >99%.

Metabolism/Excretion: Primarily metabolized via the liver by the CYP3A4 isoenzyme into 2 active metabolites (CGP62221 and CGP52421). Primarily excreted in the feces (4% as unchanged drug).

Half-Life: Midostaurin: 21 hr; CGP62221: 32 hr; CHP52421: 482 hr.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown1–3 hrunknown

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆ ⬇

mye-doe-STAW-rin

Code ⬆

NDC Code